Corteva, Inc. $CTVA Shares Bought by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management B.V. increased its stake in Corteva by 36.4% in Q4, adding 324,219 shares to hold 1,215,585 shares (about 0.18% of the company) valued at roughly $81.48 million.
• Analysts are mixed but the consensus is a “Moderate Buy” with an average price target of $83.57; Corteva reported Q4 EPS of $0.22 (in line) but missed on revenue and set FY2026 guidance of $3.45–$3.70 EPS, while trading at a $56.3B market cap, P/E ~53.1 and a 0.9% dividend yield.

Robeco Institutional Asset Management B.V. grew its stake in shares of Corteva, Inc. (NYSE:CTVA - Free Report) by 36.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,215,585 shares of the company's stock after acquiring an additional 324,219 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.18% of Corteva worth $81,481,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of CTVA. Ritholtz Wealth Management increased its position in Corteva by 6.9% during the 4th quarter. Ritholtz Wealth Management now owns 56,548 shares of the company's stock worth $3,790,000 after purchasing an additional 3,638 shares in the last quarter. Strong Tower Advisory Services increased its position in Corteva by 10.9% during the 4th quarter. Strong Tower Advisory Services now owns 47,100 shares of the company's stock worth $3,157,000 after purchasing an additional 4,627 shares in the last quarter. City Holding Co. increased its position in Corteva by 8.1% during the 4th quarter. City Holding Co. now owns 24,131 shares of the company's stock worth $1,617,000 after purchasing an additional 1,808 shares in the last quarter. Premier Path Wealth Partners LLC increased its position in Corteva by 9.7% during the 4th quarter. Premier Path Wealth Partners LLC now owns 12,005 shares of the company's stock worth $805,000 after purchasing an additional 1,058 shares in the last quarter. Finally, True North Advisors LLC increased its position in Corteva by 0.3% during the 4th quarter. True North Advisors LLC now owns 60,756 shares of the company's stock worth $4,072,000 after purchasing an additional 186 shares in the last quarter. Institutional investors and hedge funds own 81.54% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on CTVA shares. Wolfe Research increased their target price on shares of Corteva from $81.00 to $86.00 and gave the stock an "outperform" rating in a research report on Thursday, February 5th. JPMorgan Chase & Co. downgraded shares of Corteva from an "overweight" rating to a "neutral" rating and increased their price objective for the company from $75.00 to $77.00 in a research report on Thursday, February 5th. Wall Street Zen downgraded shares of Corteva from a "buy" rating to a "hold" rating in a research report on Saturday, February 7th. Zacks Research downgraded shares of Corteva from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 20th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $88.00 price objective on shares of Corteva in a research report on Thursday, February 5th. Fourteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, Corteva has an average rating of "Moderate Buy" and an average price target of $83.57.

Corteva Stock Up 0.0%

Shares of NYSE:CTVA opened at $83.86 on Monday. The company has a quick ratio of 0.96, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. Corteva, Inc. has a 52-week low of $57.00 and a 52-week high of $85.63. The company has a 50 day moving average of $78.74 and a two-hundred day moving average of $70.59. The company has a market capitalization of $56.30 billion, a price-to-earnings ratio of 53.08, a price-to-earnings-growth ratio of 2.86 and a beta of 0.68.

Corteva (NYSE:CTVA - Get Free Report) last released its earnings results on Tuesday, February 3rd. The company reported $0.22 EPS for the quarter, meeting the consensus estimate of $0.22. The company had revenue of $3.91 billion during the quarter, compared to analysts' expectations of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The business's revenue was down 1.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.32 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, analysts forecast that Corteva, Inc. will post 2.96 earnings per share for the current fiscal year.

Corteva Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 16th. Stockholders of record on Monday, March 2nd were paid a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Monday, March 2nd. Corteva's dividend payout ratio is 45.57%.

Insider Activity at Corteva

In other news, insider Brian Titus sold 8,311 shares of the stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $76.55, for a total transaction of $636,207.05. Following the completion of the transaction, the insider directly owned 8,090 shares in the company, valued at approximately $619,289.50. This represents a 50.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.15% of the company's stock.

Corteva Profile

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.